China rejected a patent application of Gilead Sciences for its hepatitis C drug Sovaldi. Advocacy group I-MAK said that the decision could pave way for other countries to reject the company's application as well.
China Rejects Patent Application Of Gilead For $1,000 A Day Hepatitis C Drug Sovaldi
Tech Times - 21 Jun 2015 14:09
China rejected a patent application of Gilead Sciences for its hepatitis C drug Sovaldi. Advocacy group I-MAK said that the decision could pave way for other countries to reject the company's application as well.
Share this Article
Recommended